MOLECULARANDCELLULARBIOLOGY,Aug.2009,p.4250–4261Vol.29,No.150270-7306/09/$08.00⫹0doi:10.1128/MCB.01581-08Copyright©2009,AmericanSocietyforMicrobiology.AllRightsReserved.NF2/MerlinIsaNovelNegativeRegulatorofmTORComplex1,andActivationofmTORC1IsAssociatedwithMeningiomaandSchwannomaGrowth䌤†MarianneF.James,1SangyeulHan,1CarolynPolizzano,1ScottR.Plotkin,2BrendanD.Manning,3AnatO.Stemmer-Rachamimov,4JamesF.Gusella,1andVijayaRamesh1*CenterforHumanGeneticResearch,MassachusettsGeneralHospital,RichardB.SimchesResearchBuilding,185CambridgeStreet,Boston,Massachusetts021141;DepartmentofNeurology2andMolecularNeuro-OncologyLaboratory,DivisionofNeuropathology,4MassachusettsGeneralHospital,55FruitStreet,Boston,Massachusetts;andDepartmentofGeneticsandComplexDiseases,HarvardSchoolofPublicHealth,665HuntingtonAvenue,Boston,Massachusetts021153Received8October2008/Returnedformodiﬁcation7January2009/Accepted12May2009Inactivatingmutationsoftheneuroﬁbromatosis2(NF2)gene,NF2,resultpredominantlyinbenignneuro-logicaltumors,schwannomasandmeningiomas,inhumans;however,mutationsinmurineNf2leadtoabroadspectrumofcanceroustumors.Thetumor-suppressivefunctionoftheNF2protein,merlin,amembrane-cytoskeletonlinker,remainsunclear.Here,weidentifythemammaliantargetofrapamycincomplex1(mTORC1)asanovelmediatorofmerlin’stumorsuppressoractivity.Merlin-deﬁcienthumanmeningiomacellsandmerlinknockdownarachnoidalcells,thenonneoplasticcellcounterpartsofmeningiomas,exhibitrapamycin-sensitiveconstitutivemTORC1activationandincreasedgrowth.NF2patienttumorsandNf2-deﬁcientmouseembryonicﬁbroblastsdemonstrateelevatedmTORC1signaling.Conversely,theexogenousexpressionofwild-typemerlinisoforms,butnotapatient-derivedL64Pmutant,suppressesmTORC1signal-ing.MerlindoesnotregulatemTORC1viatheestablishedmechanismofphosphoinositide3-kinase–Aktormitogen-activatedproteinkinase/extracellularsignal-regulatedkinase-mediatedTSC2inactivationandmayinsteadregulateTSC/mTORsignalinginanovelfashion.Inconclusion,thederegulationofmTORC1acti-vationunderliestheaberrantgrowthandproliferationofNF2-associatedtumorsandmayrestrainthegrowthoftheselesionsthroughnegativefeedbackmechanisms,suggestingthatrapamycinincombinationwithphosphoinositide3-kinaseinhibitorsmaybetherapeuticforNF2.Meningiomasaremesenchymaltumorsthatarisefromthearachnoidlayercoveringthebrainandspinalcordandaccountforapproximately30%ofallprimaryintracranialneoplasms(30).Mostsporadicmeningiomas(60%)displaysomaticinac-tivationoftheNF2gene.GermlinemutationsofNF2areassociatedwithneuroﬁbromatosis2(NF2),adominantlyin-heriteddisordercharacterizedbymultiplenervoussystemtu-mors,includingschwannomasandmeningiomas(33).Al-thoughmostmeningiomasarebenign(WHOgradeI),theyoftencausesigniﬁcantmorbidityduetocompressionoftheadjacentbrainorspinalcord.Benignmeningiomasalsohaverecurrenceratesofupto20%over10years.Tenpercentofmeningiomasareclassiﬁedasatypical(WHOgradeII)oranaplastic(WHOgradeIII)anddisplaymoreaggressiveclin-icalbehavior,withrapidgrowthandincreasedrecurrencerates(6,21).Thecurrentstandardofcareismaximalsurgicalre-section,withadjuvantradiationreservedforprogressivetu-morsorthosewithaggressivefeatures(e.g.,WHOgradeIIorIII).Thetreatmentstrategyformeningiomasthatprogressdespitesurgeryandradiationremainslimited,andcurrentlythereisnoeffectivechemotherapy.Thedevelopmentofeffectivetherapieshasbeenhampered,inpart,byourincompleteunderstandingofthesignalsinﬂuencingmeningiomacellgrowth.Enhancedexpressionofcertainpeptideandsteroidgrowthfactorsandreceptorsinmeningiomatissuesuggeststhatspeciﬁcautocrinegrowth-stimulatoryloopsmaybefunctionallyimportantinmeningiomacellproliferation(20,38).Thescarcityofestablishedmeningiomamodelsthatwouldallowfortheassessmentofgrowth-regulatorymechanismshasalsohamperedprogress.Recently,wehavedevelopedreliablemenin-giomamodelsthatovercomethechallengesofthelowgrowthratesandsenescenceofprimarybenignmeningiomacells(19).BiallelicinactivationoftheNF2geneisdetectedinthemajorityofsporadicmeningiomasandnearlyallschwannomas(11).ThetumorsuppressorgeneNF2encodesmerlin(alsocalledschwannomin),amemberoftheezrin-radixin-moesin(ERM)proteinfamilythatfunctionstolinkmembranepro-teinstothecorticalactincytoskeleton(31,41).LiketheERMproteins,merlinhasbeenimplicatedintheregulationofmem-braneorganizationandcytoskeleton-basedcellularprocessessuchasadhesion,migration,cell-cellcontact,spreading,pro-liferation,andsignaltransduction(27).Thelossofcontact-dependentinhibitionofproliferationisseeninseveraltypesofNF2-deﬁcientcells(23,29).MerlincontrolscellproliferationinresponsetocellcontactviaCD44(28)andfunctionsto-getherwiththerelatedtumorsuppressorExpandedviathe*Correspondingauthor.Mailingaddress:CenterforHumanGeneticResearch,MassachusettsGeneralHospital,RichardB.SimchesResearchBuilding,185CambridgeSt.,Boston,MA02114.Phone:(617)724-9733.Fax:(617)726-3655.E-mail:ramesh@helix.mgh.harvard.edu.†Supplementalmaterialforthisarticlemaybefoundathttp://mcb.asm.org/.䌤Publishedaheadofprinton18May2009.4250Hippo/MstpathwayinbothDrosophilaandsometypesofmammaliancells(14,49).Althoughmerlinisimplicatedinawiderangeofcellularactivities,theprecisemechanismbywhichmerlinmediatesgrowth-inhibitoryfunctionsinhumanarachnoidalandSchwanncellsandthewayinwhichitslossresultsintumorformationinNF2remainpoorlyunderstood.Werecentlyreportedthatprimaryhumanmerlin-deﬁcientmeningiomacellsexhibitastriking,enlarged-cellphenotypecomparedtononneoplasticarachnoidalcellcounterpartsde-rivedfromthesamepatient(19).Interestingly,thetuberoussclerosiscomplex(TSC)tumorsuppressorsyndromeischar-acterizedbywidespreadbenigntumorsthatpossessabnor-mallylargecells(22).MutationsinthetumorsuppressorgenesTSC1andTSC2resultinTSCsyndrome,andthecorrespond-ingproteinproducts,hamartinandtuberin(referredtoasTSC1andTSC2),functiontogetherasacomplexthatpotentlyinhibitsmammaliantargetofrapamycincomplex1(mTORC1)(17).mTORisanevolutionarilyconservedSer/Thrkinasethatexistsinoneoftwodistinctfunctionalcomplexes,TORC1andTORC2.TORC1,whichregulatesautophagy,proteintransla-tion,andribosomebiogenesis,ispotentlyandspeciﬁcallyin-hibitedbyrapamycin(10,46).TORC2,whichislesssensitivetorapamycin,isimportantforcytoskeletalregulationandAkt/proteinkinaseBactivation(16,18,36).TheTSC1-TSC2complexinhibitsmTORC1byactingasaGTPase-activatingproteinforthesmallGTPaseRheb(Rashomologenrichedinbrain).InactivationoftheTSC1-TSC2complexresultsintheaccumulationofGTP-boundRheb,whichactivatesmTORC1(10).Inadditiontonaturallyoccur-ringmutationsintheTSC1andTSC2genes,growthfactorstimulationofthephosphoinositide3-kinase(PI3K)-Aktpath-way,aswellasRas/mitogen-activatedproteinkinase(MAPK)pathways,leadstothephosphorylationandinactivationoftheTSC1-TSC2complexandconsequentactivationofmTORC1(17).TheactivationofmTORC1resultsinthephosphoryla-tionoftwowell-characterizedeffectors,eukaryotictranslationinitiationfactor4E-bindingprotein1(4EBP1)andS6kinase1(S6K1),leadingtoanincreaseinribosomalbiogenesisandtheselectivetranslationofspeciﬁcmRNApopulations.Asacrit-icalregulatorofcellgrowthandproliferation,themTORC1pathwayisdysregulatedinseveralhamartomasyndromes,aswellasinmanycancers(10).Inthisreport,weidentifytheNF2tumorsuppressorprotein,merlin,asanovelnegativeregulatorofthemTORC1pathwaytocontrolcellgrowth(cellsize).WeshowthatmTORC1isconstitutivelyactivatedinmerlin-deﬁcienthumanmeningiomacells,leadingtoincreasedcellsize.Furthermore,wesuggestthattheslowgrowthofmerlin-deﬁcientmeningiomacellsisduetoarapamycin-sensitive,mTORC1-S6K-dependentnega-tivefeedbackloopthatdiminishesPI3K-Aktsignalinginre-sponsetogrowthfactorstimulation.Theﬁndingsofthesestudiesprovideinsightintothemechanismofmerlintumorsuppressoractivityand,moreover,indicatethatrapamycinorrapamycinanalogsincombinationwithPI3Kinhibitorsmayprovidepromiseasnewtherapeuticsinthetreatmentofme-ningiomasandschwannomas.MATERIALSANDMETHODSAntibodiesandreagents.Unlessotherwisestated,allantibodieswereobtainedfromCellSignalingTechnology.ExceptionsincludecyclinD1(BDBioscience),FLAGepitope(M2,Sigma),hemagglutinin(HA)epitope(Covance),andGAPDH(glyceraldehyde-3-phosphatedehydrogenase;ChemiconInternational)antibodies.Merlinrabbitpolyclonalantibody(C26)wasdescribedpreviously(19).Growthfactorsandinhibitorswerefromthefollowingsources:insulin,wortmannin,andnocodazole,Sigma;insulin-likegrowthfactor1(IGF1),AustralBiologicals;andrapamycin,LY294002,andUO126,Calbiochem.Kinaseinhib-itorswerereconstitutedindimethylsulfoxide(DMSO)ormethanolperthemanufacturers’recommendations.Samplecollection.TissuesampleswereobtainedfromtheMassachusettsGeneralHospitaltumorrepositoryandconsistedofexcessdiscardedtissuescollectedfrompatientsundergoingclinicallyindicatedsurgeryfortumorresec-tionorspecimensfromautopsies.Tissueswereharvestedfreshfortheestab-lishmentofcelllinesasdescribedpreviously(19)and/orwereformalinﬁxedorﬂash-frozenonliquidnitrogenforhistologicalandimmunohistochemicalanal-yses.ClinicalinformationregardingdeﬁningsporadicandNF2-associatedtu-morswasbasedondiagnosesfromreferringphysicians,accordingtothepub-lishedguidelinesforthediagnosisofNF2(12).TheInstitutionalReviewBoardoftheMassachusettsGeneralHospital/PartnersHealthCareapprovedthisstudy,andinformedconsentwasobtainedfromallstudysubjects.Immunohistochemistry.Fourbenignmerlin-negativemeningiomasandﬁvevestibularschwannomaswereﬁxedwith4%paraformaldehydeinphosphate-bufferedsaline(PBS)forimmunocytochemistryanalyses.AppropriatecontrolsforantibodiesincludedDU145cellsandnormalnervetissue(negativecontrols)andPTEN-deﬁcientPC3cells(positivecontrols).Parafﬁn-embeddedtissuesec-tionswereimmunostainedusingcommercialrabbitpolyclonalantibodiestophospho-S6,recognizingS235/236and/orS240/244,underconditionsdescribedpreviously(15).Cellculture.Culturesofprimarymeningiomaandarachnoidalcellsfromfreshtissueswereestablishedasdescribedpreviously(19).MeningiomacellsweremaintainedinDulbecco’smodiﬁedEagle’smedium(DMEM)witha4.5-g/literglucosesolutioncontaining15%fetalbovineserum(FBS)and100U/mlpeni-cillinand100␮g/mlstreptomycin.Arachnoidalcellsweremaintainedinamix-tureofimprovedMEMwithL-glutamine(Richter’smodiﬁedmedium[Cellgro;Mediatech,Inc.]),15%FBS,100U/mlpenicillinand100␮g/mlstreptomycin,andinsulin(GibcoLifeTechnologies,Inc.)at4mg/liter.Humanembryonickidney293T(HEK293T)cellsweremaintainedinDMEMcontaining10%FBSand100U/mlpenicillinand100␮g/mlstreptomycin.Nf2⫺/⫺andNf2⫹/⫹mouseembryonicﬁbroblasts(MEFs)werekindlyprovidedbyA.I.McClatchey(Mas-sachusettsGeneralHospital,Boston)anddescribedpreviously(23).Thelitter-mate-derivedpairofTsc2⫹/⫹andTsc2⫺/⫺MEFsamples(bothwiththep53⫺/⫺genotype)wereprovidedbyD.J.Kwiatkowski(BrighamandWomen’sHospital,Boston,MA)anddescribedpreviously(47).TheAC007-hTERTcelllinewasdevelopedbyretrovirallytransducingprimaryarachnoidalcellswiththehumantelomerasereversetranscriptase(hTERT)genebyusingtheretroviralplasmidpBABE-puro-hTERT(7).Foraminoacidwithdrawalstudies,controlandmerlinknockdownarachnoidalcellswerecultivatedinfull-growthmediumpriortotheshiftingofcellsintoDulbecco’sPBSforthetimesindicatedinFig.2E.Forkinaseinhibitorstudies,merlinknockdownarachnoidalcellsweredeprivedofserum(in0.2%FBS)andtreatedwithrapamycin,LY294002,wortmannin,orU0126attheconcentrationsindicatedinFig.4CtoFfor30minpriortolysis.Forwortmannincontrolexperiments,arachnoidalcellsweredeprivedofserum(in0.2%FBS),pretreatedfor15minwith100nMwortmannin,andthenstimulatedfor15minwith25ng/mlIGF1.FortheanalysisofnegativefeedbackinhibitionofAkt,merlin-deﬁcientmeningiomaandmerlinknockdownarachnoidalcellsincompleteme-diumweretreatedwith10nMrapamycinfor24hpriortolysis.Fortheinsulinstimulationassay,controlandmerlinknockdownarachnoidalcellswerestimu-latedwith100nMinsulin.Constructs,virusproduction,andsiRNAs.ThegenerationofFLAG-taggedwild-type(WT)merlinisoforms1and2andmerlinmutantsexpressingS518mutations(S518AandS518D)wasdescribedpreviously(44).FLAG-taggedL64Pmutantmerlinwasgeneratedfromfull-lengthisoform1byusingtheQuikChangesite-directedmutagenesiskit(Stratagene)andsequencedtoverifytheincorporationofthechange.FLAG-taggedwild-typeTSC1andTSC2wereprovidedbyB.D.Manning.FLAG-taggedRhebandHA-S6KwerekindlyprovidedbyJosephAvruch(MassachusettsGeneralHospital,Boston).ThegenerationofalentivirusconstructexpressingWTmerlinisoform1inpCSCW2andofmerlinRNAinterference(RNAi)constructsinpLKOpuro.1wasde-scribedpreviously(19,37).LentiviralparticleswereproducedbytheNeuro-scienceVectorCoreatMassachusettsGeneralHospital.EndogenousTSC2knockdowninHEK293TcellswascarriedoutusingSMARTpoolsmallinter-feringRNAs(siRNAs)perthesuggestionofthemanufacturer(Dharmacon).VOL.29,2009NF2/MERLINREGULATESmTORC1SIGNALING4251Transfectionsandinfections.MammaliantransfectionsusingHEK293Tcells,includingthosewithsiRNAs,wereperformedusingLipofectamine2000asrecommendedbythemanufacturer(Invitrogen).Transfectedcellsweremain-tainedinfull-growthmediumfor48hpriortolysis.Fortheinsulinstimulationexperiments,cellswereserumstarved(in0%FBS)forthelast24-hperiodandthenstimulatedwith100nMinsulinfor15min.TheimmunoprecipitationofHA-S6Kwasperformedusinganti-HAantibody(seeFig.5D).IsogenicpairsofcontrolandmerlinknockdownarachnoidalcellsamplesweregeneratedbytheinfectionofprimaryarachnoidalcellsorAC007-hTERTcellswithlentivirusescontaininganonspeciﬁcscrambledtargetsequence(scr)oramerlin-speciﬁcRNAitargetsequence(m5,m6,orm8)(19).Cellswereinfectedatamultiplicityofinfection(MOI)of10andselectedwithpuromycin(0.4␮g/ml)toobtainstablepools.Unlessotherwisestatedinthetext,controlscrandmerlin(m5)RNAiarachnoidalcellswereserumdeprived(in0.2%FBS)onday7postinfectionandharvestedthefollowingdaytoobtainproteinlysates.Merlin-deﬁcientmeningiomacellsandTsc2⫺/⫺MEFswereinfectedwithmerlinisoform1ataMOIof50or100bylentivirus(pCSCW2)-baseddeliveryandthenharvested3dayspostinfectiontoobtainproteinlysates.Proliferationassays.TodetectNf2⫹/⫹andNf2⫺/⫺MEFcellsinSphase,5-bromo-2⬘-deoxyuridine(BrdU)incorporationwasquantiﬁedusingtheinsitucellproliferationkitFLUOSaccordingtothespeciﬁcationsofthemanufacturer(Roche,Mannheim,Germany).Nf2MEFcellswereplatedontopoly-D-lysine-coatedcoverslips,treatedwithDMSOorrapamycin(20nM)for24h,andincubatedwith10␮MBrdUfortheﬁnal4h.BrdUincorporationwasdetectedusingaﬂuorescein-conjugatedanti-BrdUantibody.BrdU-positiveandDAPI(4⬘,6-diamidino-2-phenylindole)-positivecellsinﬁverandomlychosenﬁeldsperconditionwerecountedusingaTCSSP5confocalmicroscope(Leica,Wetzlar,Germany),andthepercentagesofBrdU-positivecellswerecalculated.Alltheexperimentswereperformedintriplicate.StatisticalanalyseswerecarriedoutusingStudent’stwo-tailedttest.Celllysisandimmunoblotting.MeningiomaandarachnoidalcellsandTsc2MEFcellswereharvestedtoobtaincelllysatesasdescribedpreviously(19).Proteinswereresolvedbysodiumdodecylsulfate-polyacrylamidegelelectro-phoresis,transferredontonitrocellulosemembranes(Bio-Rad),andsubjectedtoimmunoblotanalysesusingappropriateantibodies,horseradishperoxidase-con-jugatedsecondaryantibodies,andanenhancedchemiluminescence(ECL)de-tectionsystem(AmershamPharmaciaBiotechnology).Cellsizeandcellcycleanalysis.Thesizesofprimarymerlinknockdownarachnoidal(AC030)cellsrelativetothoseofscrcontrolcellswithorwithoutrapamycintreatmentweredeterminedbyﬂuorescence-activatedcellsorter(FACS)analyseswithaFACSCaliburinstrument(BectonDickinson)usingforwardscatterheight(FSC-H)values.Stablecellpopulationsweretreatedwith5nMrapamycineveryotherdayfor7days.Cellsweretrypsinizedandresus-pendedinPBScontaining3%FBSand5mMEDTA.Atotalof20,000cellswerecollected,andthemeanFSC-HvalueswereobtainedusingCellQuestsoftware.CellswerestainedbypropidiumiodideforFACSanalysestodeterminethecellsizesinG1-andG2/M-phasepopulations.Culturedmeningiomaandmerlinknockdownarachnoidalcellstreatedwithandwithoutrapamycinwerevisualizedbyphase-contrastimagingusingaNikonEclipseTE2000-UinvertedmicroscopeandphotographedusingaSPOTRTslidercharge-coupleddevicecameraandSPOTimagingsoftware(DiagnosticInstrumentsInc.).RESULTSRapamycininhibitsthegrowthofmerlin-deﬁcientarachnoi-dalandmeningiomacellsinvitro.Werecentlyreportedthathumanprimarymerlin-deﬁcientmeningiomacellsareen-largedduringculturingcomparedtomatchednormalarach-noidalcells.Similarly,arachnoidalcellsinwhichmerlinexpres-sionissuppressedbecomedramaticallylargerthancellstreatedwithcontrolRNAiconstructs(19).Theseﬁndingssug-gestthatpathwaysregulatingincreasedcellsizemaybenega-tivelyregulatedbymerlin.SincetheactivationofthemTORC1pathwayhasemergedasaconservedregulatorymechanisminthecontrolofcellsize(45),weexaminedwhetherthemTORC1-speciﬁcinhibitorrapamycinwouldcounterthein-creasedsizesofmerlin-deﬁcientNF2targetcelltypes.Treat-mentwithrapamycin,ataconcentrationaslowas1nM,concurrentwiththeinitiationofstableknockdownofmerlininarachnoidalcellsblockedanincreaseincellsizecomparedtothatofuntreatedmerlinknockdowncells(Fig.1A).Ananal-ysisofrelativecellsizesbyﬂowcytometryusingthemeanFSC-Hasaparameterdemonstratedthatarachnoidalcellsinwhichmerlinwassuppressedweresigniﬁcantlylargerthancontrolcells,asindicatedbyarightwardshiftinthemeanFSC-H(Fig.1B,left).Rapamycinabolishedtheeffectofmer-linknockdownoncellsize(Fig.1B,right).Additionally,weobservedthatenlarged,activelydividingmerlinknockdownarachnoidalcellstreatedwithrapamycinfor4daysrevertedtoastrikinglysmallersize(seeFig.S1inthesupplementalma-terial).Thereversalofthephenotypeofcellenlargement,relativetothesizesofuntreatedcells,inculturesofmerlin-deﬁcientmeningiomacellstreatedwithrapamycinwasalsoobserved(Fig.1C).TheseﬁndingsindicatethattheinhibitionofmTORC1byrapamycincannotonlypreventbutalsore-verseincreasesinthesizesofmerlin-deﬁcientarachnoidalandmeningiomacells.Merlin-deﬁcientcellsexhibitconstitutivemTORC1signal-ing.WenextexaminedwhetherthemTORC1signalingpath-wayinmerlin-deﬁcientNF2targetcellswasdysregulated.ThelevelsofphosphorylationofribosomalproteinS6,anindicatorofmTORC1activity,inthreeprimarymerlin-deﬁcientmenin-giomacellcultureswereelevatedcomparedtothoseinthreenormalprimaryarachnoidalcelllinesunderconditionsofse-rumdeprivation(Fig.2A).ToexaminewhethertheincreaseinmTORC1signalingwasduetomerlinloss,wesuppressedmerlininarachnoidalcellsbyusingthreedifferenttargetingshorthairpinRNAs(shRNAs;m5,m6,andm8).Thissuppres-sionproducedanincreaseinthephosphorylationofS6atSer235/236andatSer240/244(sequentialS6Ksubstratephos-phorylationsitesofS6)comparedtothatincontrol(scr)RNAiarachnoidalcellsunderconditionsofserumdeprivation.Con-sistentwithincreasedmTORC1-dependentphosphorylationofS6,weobservedincreasedphosphorylationatS2448ofmTORandT389ofp70-S6K,adirectmTORC1substrate,inmerlinknockdowncellscomparedtothatincontrolcells(Fig.2B).Merlinsuppressioninthesecellsalsoresultedindecreased4EBP1mobility(anindicatorofphosphorylation)comparedtothatincontrolcells,conﬁrmingthatbotharmsregulatingmTORC1-mediatedproteinsynthesisareenhanced(Fig.2C).Additionally,wedetectedincreasedexpressionofcyclinD1,adownstreamtargetofmTORC1(1),inmerlinknockdowncells.TheseﬁndingssuggestthatmTORC1isactivatedinagrowthfactor-independentmannerinmerlin-deﬁcientcells.Wetestedwhethermerlinsuppressionresultedinincreasedcellsizeindifferentphasesofthecellcycle.ThesuppressionofmerlinwithtwodifferentshRNAsinarachnoidalcellscausedanincreaseincellsizeinG1andG2/Mphasesofthecellcycle(Fig.2D),indicatingthatcellsizeandaberrantmTORC1signalinginmerlin-deﬁcientcellsdonotreﬂectcellcyclechangesandrepresentbonaﬁdeeffectsonmTORC1.Wealsoexaminedifmerlin-deﬁcientcellsexhibitedelevatedmTORC1signalingcomparedtothatincontrolarachnoidalcellsunderlow-serumconditionsafterSphasearrest,bytreatingcellswithnocodazolefor24hpriortoreplatingthecellsin0.2%FBS–DMEMforanadditional24h.Undertheseconditions,merlin-deﬁcientcellsexhibitedtheactivationofmTORC1,eliminat-ingthepossibilityofmitogenicinputunderlow-serum4252JAMESETAL.MOL.CELL.BIOL.conditions(seeFig.S2inthesupplementalmaterial).WenextexaminedwhetherS6phosphorylationwasappropriatelyter-minatedintheabsenceofnutrientsinNF2-deﬁcientcells.AminoaciddeprivationblockedmTORC1signalinginboththecontrolandmerlinknockdownarachnoidalcells(Fig.2E),suggestingthatmerlindoesnotregulatemTORC1throughnutrient-sensitivepathways.Merlin-deﬁcientmeningiomasandvestibularschwannomasexhibitaberrantmTORC1signalinginvivo.TodeterminewhethermTORC1signalingisaberrantlyregulatedinNF2-associatedtumors,weexaminedthestatusofS6phosphoryla-tioninfourNF2-deﬁcientbenignmeningiomasandﬁveves-tibularschwannomasbyimmunohistochemistryanalyses.Phospho-S6immunostainingofNF2-deﬁcientmeningiomasFIG.1.Rapamycininhibitsthegrowthofprimarymerlin-deﬁcientarachnoidalandmeningiomacells.(A)Primarycontrol(scrRNAi)andmerlinknockdown(m5RNAi)arachnoidal(AC030)cellsweretreatedwithorwithoutrapamycinstartingatday2postinfectionwithlentivirusesexpressingshRNAsandeveryotherdaythereafterfor12days.Phase-contrastimagesdemonstrateanincreaseinthesizesofuntreated(vehicle-treated)merlinRNAiarachnoidalcellscomparedtothoseofscrRNAiarachnoidalcells(originalmagniﬁcation,⫻10).Rapamycin(1and20nM)inhibitstheincreaseinthesizesofmerlinRNAicellscomparedtothoseofvehicle-treatedmerlinRNAiarachnoidalcells.(B)Primarycontrolandmerlinknockdownarachnoidal(AC030)cells,treatedwith(⫹)orwithout(⫺)rapamycin(Rap;10nM)everyotherdayfor10days,wereevaluatedbyFACSanalysestodeterminerelativecellsizes.ThexaxesindicaterelativecellsizesaccordingtoFSC-Hvalues.(Left)Merlinm5RNAiincreasesthesizesofarachnoidalcells,asdeterminedbytherightwardshiftinthemeanFSC-Hhistogramcomparedtothatforcontrolscr-treatedarachnoidalcells.(Right)Rapamycinabolishestheeffectofmerlinm5RNAioncellsize.(C)Theenlargementofcellsinprimarymerlin-deﬁcientMN304meningiomaculturestreatedwithvehicleonlyisinhibitedbytreatmentwithrapamycin(10nM)everyotherdayfor7days(originalmagniﬁcation,⫻10).VOL.29,2009NF2/MERLINREGULATESmTORC1SIGNALING4253showeddiffusecytoplasmicpositivestaining,consistentwiththeactivationofthemTORC1pathway(Fig.3).Thevestibularschwannomasdisplayedafocalstainingpatternwithareasofstrongphospho-S6positivity.Normalnervetissueemployedasanegativecontroldidnotshowphospho-S6staining.Similarpatternsofphospho-S6immunostainingwereobtainedusingantibodiesrecognizingphosphorylationatbothSer235/236andSer240/244.ThesedatasuggestthatmTORC1isactivatedinvivoinNF2-associatedschwannomasandmeningiomas.mTORC1activationuponmerlinlossisPI3K-AktandMAPK/extracellularsignal-regulatedkinase(ERK)indepen-dent.Wenextsoughttounderstandthemechanismofconsti-tutive,growthfactor-independentactivationofmTORC1sig-nalinginmerlin-deﬁcientcells.Sincegrowthfactor-initiatedmTORC1signalingiscommonlymediatedbyupstreamacti-vationofPI3K-Akt,weexaminedwhetherthePI3K-Aktsig-nalingcascadewasdysregulatedinNF2targetcells.Weob-servedthatAktwasnotphosphorylatedatSer473ineitherFIG.2.ThemTORC1pathwayisaberrantlyactivatedinmerlin-deﬁcientNF2targetcelltypesinagrowthfactor-independentmannerbutissensitivetonutrientdeprivation.(A)Threeprimaryarachnoidal(AC028,AC030,andAC032)andthreeprimarymerlin-deﬁcient[merlin(⫺)]meningioma(MN380,MN383,andMN302)celllinesweredeprivedofserum(in0.2%FBS)overnightpriortobeingharvestedtoobtainproteinlysates.S6,acommonmarkerofmTORC1activation,exhibitselevatedphosphorylationinmerlin-deﬁcientMNcellscomparedtothatinnormalarachnoidalcells,withnochangeintotalS6proteinlevels.GAPDHproteinlevelsdemonstrateequivalentsampleloading.p-S6(S235/236),S6phosphorylatedatS235/236.(B)Arachnoidalcellsstablyexpressingthreedifferentlentivirus-mediatedshRNAs(m5,m6,andm8)targetingmerlinexhibitincreasedphosphorylationofmTOR(S2448)andmTORC1effectorsp70-S6K(atThr389)andS6(atS240/244andS235/236),aswellascyclinD1,adownstreamtargetofmTORC1,uponmerlinknockdowncomparedtothatincontrol(scrRNAi)cellsunderconditionsofserumdeprivation(in0.2%FBS).TotallevelsofmTOR,S6,andS6Kproteinswereunchanged.p-mTOR(S2448),mTORphosphorylatedatS2448;p-S6K(T389),S6KphosphorylatedatT389;p-S6(S240/244)andp-S6(S235/236),S6phosphorylatedatS240/244andS235/236,respectively.(C)Merlinknockdowninarachnoidalcells(bym5,m6,andm8)resultsinincreasedaccumulationofphosphorylatedspeciesof4EBP1comparedtothatinscrcontrolRNAicellsunderconditionsofserumdeprivation(in0.2%FBS).4EBP1phosphorylation(detectedbyanti-4EBP1antibody)isreﬂectedby4EBP1electrophoreticmobilityresults.(D)CellcycleevaluationbyFACSanalysisdemonstratesincreasedsizesofmerlinknockdowncells(expressingm5andm8shRNAs)comparedtothoseofscrcontrolcellsinG1andG2/Mphasesofthecellcycle.(E)Toexamineeffectsofmerlindeﬁciencyonnutrientdeprivation,control(scr)andmerlinRNAi(m5)knockdownarachnoidalcellsweregrownovernightwithfullserum(15%FBS)priortobeingshiftedintoDulbecco’sPBSfor0,20,40,or60min.ThephosphorylationofS6(atS240/244)isappropriatelyterminatedinmerlinRNAiarachnoidalcells,similartothatincontrolscrcells.⫺aa,aminoaciddeprivation.4254JAMESETAL.MOL.CELL.BIOL.merlin-deﬁcientmeningiomacellsormerlinknockdownarach-noidalcells,similartothatincontrolarachnoidalcells(Fig.4AandB).Consistentwiththeseﬁndings,PRAS40,adownstreameffectorofAkt(35,42),wasnotphosphorylated(Fig.4B).Tuberin,adirectsubstrateofAkt,alsowasnotphosphorylatedatT1462inmerlinknockdownarachnoidalcells(datanotshown).Inaddition,wedidnotobserveaberrantactivationofvariousgrowthfactorreceptorsuponmerlinloss,consistentwiththeabsenceofAktactivation(seeFig.S3inthesupple-mentalmaterial).Collectively,thesedatasuggestthatPI3K-Aktsignalingisnotdysregulatedinmerlin-deﬁcientmeningi-omacellsandthereforedoesnotcontributetoaberrantmTORC1signaling.Wethenexaminedmerlin-deﬁcientcellsforconstitutiveMAPKsignalingsincepositivegrowthsignalsfromtheRas/MAPKpathwaycanalsostimulatemTORC1activity.ERK-speciﬁcactivationofmTORC1involvesmultisitephosphory-lationoftuberinbybothERKanditsdownstreamtargetp90ribosomalS6kinase(25,32).Interestingly,wedetectedcon-stitutiveERK1/ERK2phosphorylationinbothmerlin-deﬁ-cientmeningiomacellsandmerlinknockdownarachnoidalcells,comparedtocontrolarachnoidalcells,underconditionsFIG.3.Merlin-deﬁcientmeningiomasandvestibularschwannomasexhibitconstitutiveS6phosphorylation.Patient-derivedmerlin-deﬁcientmeningioma(MN258⫺/⫺andMN336⫺/⫺)andvestibularschwannoma(xT1640)tissueswerestainedimmunohistochemicallytodetectS6phos-phorylation(atS240/244andS235/236).Dataarerepresentativeofresultsforfourbenignmerlin-deﬁcientmeningiomasandﬁvebenignvestibularschwannomas.Sectionsofnormalnervetissue(negativecontrol)didnotexhibitS6phosphorylation(originalmagniﬁcation,⫻40).VOL.29,2009NF2/MERLINREGULATESmTORC1SIGNALING4255ofserumdeprivation(Fig.4AandB),suggestingthatmerlinmayregulatemTORC1activitythroughtheRas/MAPKsig-nalingpathway.TofurtherassesstheinvolvementofupstreamsignalingpathwaysintheaberrantactivationofmTORC1signalinginmerlin-deﬁcientcells,weexaminedS6phosphorylationinthepresenceofpharmacologicalinhibitorsthatspeciﬁcallytargetthesepathways.Asexpected,theinappropriateactivationofS6inmerlinknockdownarachnoidalcellswasinhibitedbyrapa-mycin,demonstratingdependenceonmTORC1(Fig.4C).Inaddition,wefoundthatthePI3KinhibitorLY294002blockedS6activation(Fig.4D).SincemTOR,aPI3K-relatedenzyme,isdirectlyinhibitedbyLY294002tothesameextentasPI3Ks(4,43),weexaminedtheresponseofS6activationtowortman-FIG.4.Merlin-deﬁcientmTORC1activationisPI3K-AktandMAPK/ERKindependent.(AandB)Merlin-deﬁcientmeningioma[merlin(⫺)MN](A)andmerlinknockdown(m5,m6,orm8RNAi)(B)arachnoidalcellsexhibitelevatedERK1/ERK2phosphorylationcomparedtothatincontrol(scrRNAi)arachnoidalcells.Incontrast,merlin-deﬁcienttargetcellsexhibitnochangeinthephosphorylationofAkt(AandB)orPRAS40(B),asubstrateofAktandanegativeregulatorofmTORC1,comparedtothatincontrolarachnoidalcells.CellsweretreatedasdescribedinthelegendtoFig.2AandB.(CtoF)Control(scrRNAi)andmerlinknockdown(m5RNAi)arachnoidalcellsweredeprivedofserum(in0.2%FBS)overnight,andthemerlinknockdowncellswerethenincubatedwiththeindicatedconcentrationsofrapamycin(Rap),LY294002,wortmannin(Wm),andUO126for30min.CelllysateswereassayedforS6phosphorylationbyimmunoblotanalyses.⫺,absent.(C)ThemTORC1-speciﬁcinhibitorrapamycinblocksconstitutiveS6activation.(D)ThePI3KinhibitorLY294002blocksS6activationbutdoesnotaffectMAPK/ERKsignaling.(E,top)WortmannindoesnotblockS6activation,indicatingthatmTORC1activationisindependentofPI3K-Aktsignaling.(Bottom)WortmanninpotencyisdemonstratedbytheinhibitionofIGF1-stimulatedAktphosphorylationinarachnoidalcellspretreatedwithwortmannin(100nM),incontrasttothatinuntreatedcells.(F)U0126,aMEK1/MEK2inhibitor,blocksERK1/ERK2phosphorylationbuthasnoeffectonS6phosphorylation.4256JAMESETAL.MOL.CELL.BIOL.nin,whichexhibitsrelativelyhighspeciﬁcityforPI3Ksatcon-centrationsof20to50nM.Inthepresenceof25to200nMwortmannin,wedetectednoinhibitionofS6activationinmer-lin-deﬁcientcells(Fig.4E),conﬁrmingthatPI3K-AktsignalingdoesnotcontributetoconstitutivemTORC1activation.Wort-manninpotentlyinhibitedIGF1-stimulatedAktactivationinpretreatedarachnoidalcells,demonstratingwortmannin’sef-fectiveness(Fig.4E,bottom).Additionally,wefoundthatnei-therLY294002norwortmanninhadanyeffectonERK1/ERK2phosphorylation,indicatingthatERKactivationwasnotdependentonPI3Ksignaling(Fig.4Danddatanotshown).TodeterminewhetherthemechanismofconstitutivemTORC1activationinmerlin-deﬁcientcellsisdependentonRas/MAPKsignaling,wetreatedcellswiththeMEK1/MEK2inhibitorcompoundUO126.UO126completelyinhibitedERK1/ERK2signalinginadose-dependentmannerwithoutaffectingS6phosphorylation,indicatingthatmerlindoesnotregulatemTORC1throughRas/MAPK-dependentsignalingpathways(Fig.4F).Together,theseresultsconﬁrmthatmTORC1activationinmerlin-deﬁcientcellsisnotmediatedbytheactivationofeitherPI3K-AktorRas/MAPKsignalingpathways.ExogenousmerlinexpressioninhibitsmTORC1signaling.Todeterminewhethermerlinoverexpressioncouldinhibitgrowthfactor-mediatedmTORC1activation,full-lengthmer-linisoform1orisoform2wascoexpressedwiththeHA-S6Kreporterininsulin-stimulatedHEK293Tcells.Consistentwiththeﬁndingsofpreviousstudies,RheboverexpressionpotentlyactivatedmTORC1signaling,asindicatedbyS6K(T389)phosphorylation,whereasTSC1andTSC2coexpressioninhib-itedS6Kphosphorylation(Fig.5A).BothmerlinisoformsstronglyinhibitedS6Kactivation(Fig.5A).WenextexaminedwhetheranNF2patient-derivedL64Pmissensemutantorei-theroftwomerlinS518phosphomutantsexpressingS518AorS518D,thoughttorendermerlinactiveorinactive,respec-tively,asatumorsuppressorprotein(39,40),isabletoblockmTORC1activation.Undergrowthconditionswithfullserum,WTmerlinblockedmTORC1activationrelativetothatincellsexpressingacontrolvector;however,theL64PNF2mutantproteindidnot.SimilartoWTNF2protein,bothS518phos-phomutantswerecapableofsuppressingmTORC1activity(Fig.5B).Inagreementwiththisﬁnding,thereintroductionofWTNF2proteinintoNF2-deﬁcientmeningiomacellsbylen-tivirus-mediateddeliveryinhibitedendogenousS6phosphory-lationunderconditionsofserumdeprivation(Fig.5C).Col-lectively,theseﬁndingsshowthatmerlinlossleadstotheactivationofmTORC1andthattheectopicexpressionofei-thermerlinisoform1or2inhibitsmTORC1signaling.WenextexaminedwhethermerlincouldinhibitmTORC1activationinTSC1-TSC2-deﬁcientcells.Asexpected,TSC2knockdownviasiRNAexpressionresultedinincreasedS6K(T389)phosphorylationinHEK293cells;however,NF2pro-teinexpressioninTSC2knockdowncellswasunabletoblockS6Kactivationundergrowthconditionswithfullserum(Fig.5D).Similarly,NF2proteinoverexpressiondidnotinhibitcon-stitutiveS6KactivityinTSC2nullMEFs(Fig.5E),indicatingthatmerlindoesnotresidedownstreamoftheTSC1-TSC2complex.TodeterminewhetherNF2proteinoverexpressioncouldblockRheb-mediatedactivationofmTORC1,wecoex-pressedRhebandNF2protein.AsshowninFig.5F,merlindidnotinhibitelevatedmTORC1activityresultingfromRheboverexpression,conﬁrmingthatmerlinisnotdownstreamofTSC-Rheb.Merlin-deﬁcientcellsexhibitnegativefeedbackregulationofPI3K-Aktsignaling.LikeTSC,NF2isatumorsyndromeinvolvingpredominantlybenignlesions.OnelineofthoughtisthatthelimitedmalignantpotentialofTSC-associatedtumorsisduetotheattenuationofAktsignaling(17).Weexaminedwhethermerlin-deﬁcientcellsweredefectiveingrowthfactor-mediatedactivationofAkt.Weobservedthat,inresponsetoinsulinstimulation,atime-dependentincreaseinAktandS6phosphorylationincontrolRNAiarachnoidalcellsoccurredbutthatAktstimulationwasimpairedinmerlinknockdownarachnoidalcells(Fig.6A).Merlinknockdowncellsdemon-stratedconstitutiveS6activation,withnofurtheractivationinresponsetoinsulinstimulation.ProlongedexposuretothemTORC1-speciﬁcinhibitorrapamycinenhancesPI3K-Aktac-tivationinmanycelllinesbyrelievingphospho-S6K-mediatedPI3K-Aktfeedbackinhibition(26).Theexposureofmerlin-deﬁcientmeningiomacellsandmerlinRNAiarachnoidalcellstorapamycinfor24hresultedintheactivationofAkt(Fig.6B).Collectively,thesedataareconsistentwiththeexistenceofabasalmTORC1-dependentnegativefeedbackloopinmer-lin-deﬁcientcells.Furthermore,rapamycintreatmentresultedindecreasedcyclinD1expressioninbothmerlin-negativeme-ningiomacellsandarachnoidalcellsinwhichmerlinwassup-pressed,indicatingthattheelevationofcyclinD1inmerlin-deﬁcientcellsispartiallymTORC1dependent(Fig.6B,bottom).Nf2ⴚ/ⴚMEFsexhibitconstitutivemTORC1activationandrapamycin-sensitiveproliferation.WealsoexaminedmTORC1signalinginNf2⫺/⫺MEFsandfoundthat,similartohumancelltypes,Nf2-deﬁcientMEFsexhibitedconstitutiveactivationofmTORC1signaling,incontrasttoWTNf2⫹/⫹MEFs,asindicatedbyphospho-S6levelsandthephosphorylationstatusof4EBP1(Fig.7AandB).Furthermore,theobservedincreaseintheproliferationofNf2-deﬁcientMEFscomparedwiththatofNf2⫹/⫹MEFswassigniﬁcantlyreducedwhentheNf2-deﬁ-cientMEFsweretreatedwith20nMrapamycin(Fig.7C),suggestingthattheactivationofmTORC1signalingpartlycontributestotheenhancedproliferationofthesecells.DISCUSSIONInthisstudy,weprovideevidencethattheNF2tumorsup-pressormerlinactsasanovelnegativeregulatorofmTORC1.MerlindeﬁciencyresultsintheconstitutiveactivationofmTORC1signalinginhumanarachnoid/meningiomacellsintheabsenceofgrowthfactorsbuthasanegligibleeffectonnutrient-dependentmTORC1activation.Contrarytothecon-ceptthatunphosphorylatedmerlinisoform1(lackingphos-phorylationatS518andexhibitingaclosedconformation)andnotisoform2isresponsibleforthetumorsuppressorfunction(39,40),wefoundnofunctionaldistinctionintheabilitiesofthemerlinisoformsorthephospho-S518merlinmutants(theS518AandS518Dproteins)tosuppressmTORC1signaling.OurﬁndingsindicatethatneithertheisoformtypenortheS518phosphorylationstatuspredictstumorsuppressoractivityasdeﬁnedbyaberrantmTORC1signaling.Thisresultiscon-sistentwiththeabsenceofNF2-causingmutationsinthecar-VOL.29,2009NF2/MERLINREGULATESmTORC1SIGNALING4257boxy-terminalregionscorrespondingtotheexons(16and17)thatdistinguishthetwoisoforms.AlthoughtheMAPK/ERKsignalingpathwayisaberrantlyregulatedinmerlin-deﬁcientcells,wefoundthatmTORC1activationduetomerlinlossisindependentofeitherPI3K-AktorMAPK/ERKsignaling.TheresultsofourstudiessuggestthatmerlinmayfunctionupstreamoftheTSC1-TSC2complex,themajormTORC1regulatorinthecell.OurdataareconsistentwiththemodelthatmerlinsignalsthroughTSC-RhebtoregulatemTORC1.Merlin-deﬁcientcellsresembleTSCnullcellsinthatthelossofeithertumorsuppressorresultsinhighlevelsofconstitutivemTORC1signaling,adeﬁnitiveabsenceofAktphosphoryla-FIG.5.MerlinexpressioninhibitsmTORC1signaling.(A)HEK293TcellswerecotransfectedwithHA-S6Kandvectoronly(V)orFLAG-taggedRheb,TSC1-TSC2,orNF2proteinisoform1(NF2iso1)orisoform2(NF2iso2).After24h,cellsweresubjectedtoserumstarvation(0%FBS)overnightandstimulatedwithinsulin(150nM)for15min.BothNF2proteinisoformsinhibitS6Kphosphorylationcomparedtothatincellsexpressingthevectoronly.RhebexpressionactivatesandTSC1-TSC2expressioninhibitsthemTORC1pathway.(B)HEK293TcellswerecotransfectedwithHA-S6KandvectoronlyorFLAG-taggedWTNF2proteinormutantNF2proteinconstructsexpressingL64P,S518A,orS518D.SimilartoWTNF2protein,NF2mutantproteinsexpressingS518AandS518DinhibitS6Kactivationinfull-growthmedium(10%FBS),butapatient-derivedmutant(L64P)proteindoesnot.p-NF2(S518),NF2proteinphosphorylatedatS518.(C)Merlin-deﬁcientmeningioma[merlin(⫺)MN]cellsweretransducedwithvectoronlyorNF2protein(MOI,50)andsubjectedtoserumstarvation(0%FBS)overnight.NF2protein-infectedcellsexhibittheinhibitionofS6phosphorylationcomparedtothatinvector-infectedcells.(D)HEK293TcellswerecotransfectedwithHA-S6KandvectoronlyorFLAG-NF2protein,TSC2siRNA(TSC2si),orFLAG-NF2proteinandTSC2siRNAstogether(NF2⫹TSCsi).ImmunoblotanalysesofHAimmunoprecipitations(IP)usingananti-HAantibodyindicatethatS6KphosphorylationisnotinhibitedbyNF2proteininTSC2siRNA-expressingcellsinfull-growthmedium.ThedecreaseinlevelsofS6KphosphorylatedatT389intheNF2⫹TSC2silanecomparedtothoseintheTSC2silaneisduetoreducedlevelsofHA-S6Kexpression.(E)Tsc2⫺/⫺MEFswereinfectedwithvector(MOI,50)orNF2protein(MOIs,50and100)asdescribedinthelegendtopanelC.NF2proteindoesnotinhibitS6KorS6phosphorylationcomparedtothatinvector-infectedcells.Lanes⫺,untransfectedcells.(F)AmongHEK293TcellstransfectedasdescribedinthelegendtopanelD,thosecoexpressingNF2proteinandRhebshownoinhibitionofS6Kphosphorylation.4258JAMESETAL.MOL.CELL.BIOL.tionatS473,andenlargedcells.Merlindeﬁciencyinhumancells,similartoTSCdeﬁciency,resultsinlowerproliferationratesthanthoseoftheirWTcounterpartsundergrowthcon-ditionswithfullserum,perhapsduetotheirdecreasedrespon-sivenesstoserum(19,48).AlthoughthemechanismbywhichmerlinregulatesTSC1-TSC2isunclear,hamartinwasshownpreviouslytointeractwiththeERMfamilyproteinsandtoweaklybindmerlin(13,24).TheTSC1-TSC2proteincomplexhasalsobeenshowntomodulateactincytoskeletonprocesses,focaladhesions,andcellmigration(9),cellularactivitiesthatarealsoregulatedbymerlin/ERMproteins(3,27).ArecentstudysuggestedthatTSC2isinhibitedbyAkt-mediatedphos-phorylationbybeingsequesteredinthecytoplasm,awayfromitsmembrane-boundpartnershamartinandRheb(5).Furtherinvestigationsarenecessarytounderstandwhethermerlinde-ﬁciencyresultsinmTORC1activationbyalteringthelocaliza-tionofTSC1orTSC2,bycausingthedissociationoftheTSC1-TSC2complex,and/orbyaffectingtheRheb–GTPase-FIG.6.AktsignalingisattenuatedincellslackingNF2proteinduetomTORC1-mediatednegativefeedbackinhibition.(A)Control(scrRNAi)andmerlinknockdown(m5RNAi)arachnoidalcellsweredeprivedofserum(in0.2%FBS)overnightandstimulatedwithinsulin(100nM)forthetimesindicated.scrRNAiarachnoidalcellsexhibitatime-dependentincreaseinactivatedAkt(S473)andS6(S235/236)phosphorylation,incontrasttomerlinknockdownarachnoidalcells,whichexhibitimpairedAktphosphorylationandconstitutiveS6activationthatisinsensitivetoinsulinstimulation.(B)Merlin-deﬁcientmeningioma[merlin(⫺)MN]cellsandcontrol(scr)andmerlin(m5)RNAiarachnoidalcellswereincubatedwith(⫹)andwithout(⫺)rapamycin(Rap;10nM)for24h.Untreatedcellsincompletemedium(15%FBS)exhibitS6phosphorylation(atS240/244)andtheattenuationofAktphosphorylation(atS473),resultingfromconstitutiveactivationofanmTORC1-S6Knegativefeedbackloop.Inthepresenceofrapamycin,mTORC1-S6Ksignalingisblocked,preventingS6phosphorylation,andAktphosphorylationisrestoredbyrelieffromnegativefeedback.Underserum-free(SF;0%FBS)conditions,merlin-deﬁcientmeningiomacellsdonotexhibittherestorationofAktsignaling.Inaddition,cyclinD1levelsarereducedinrapamycin-treatedcells,suggestingthatexpressionis,inpart,mTORC1dependent.FIG.7.Nf2-deﬁcient(Nf2⫺/⫺)MEFsexhibitconstitutivemTORC1activationcomparedtoNf2WT(Nf2⫹/⫹)MEFs.(A)Nf2⫺/⫺MEFs,platedconﬂuentlyandsubconﬂuently(subconﬂ),exhibitconstitutiveS6activation,incontrasttoNf2⫹/⫹MEFs,underconditionsofserumstarvation(0%FBS).(B)Nf2⫺/⫺MEFsandTsc2⫺/⫺MEFsexhibitincreasedaccumulationofphosphorylatedspeciesof4EBP1comparedtothatincontrolNf2⫹/⫹andTsc2⫹/⫹MEFs,respectively,underconditionsofserumstarvation(0%FBS).4EBP1phosphorylation(detectedbyanti-4EBP1antibody)isreﬂectedby4EBP1electrophoreticmobilityresults.(C)Rapamycin(Rap)suppressestheproliferationofNf2⫺/⫺MEFcells.Nf2⫹/⫹andNf2⫺/⫺MEFsincubatedwith20nMrapamycinorvehicle(DMSO)for24hwereexaminedforS-phaseentrybyusingBrdUincorporationasdetailedinMaterialsandMethods.DataarepresentedasmeanpercentagesofDAPI-stainedcells⫾standarderrorsofthemeans.*,P⬍0.01forDMSO-treatedcontrolversusrapamycin-treatedgroupsorNf2⫹/⫹versusNf2⫺/⫺MEFcells(n⫽5);⫹,present;⫺,absent.VOL.29,2009NF2/MERLINREGULATESmTORC1SIGNALING4259activatingproteinactivityoftuberin.However,wecannotruleoutthepossibilitythatmerlinmaysignalthroughaparallelpathway(independentofTSC)toregulatemTORC1.ItisalsotemptingtospeculatethatasshownrecentlyforTSCproteins(16),merlinmayalsoregulatemTORC2,whichmayexplainthecytoskeletaldefectscommonlyobservedinNF2protein-deﬁcientcells.OurdataidentifymerlinasyetanothertumorsuppressorproteinthatrestrictsmTORC1signaling.Ithasbeensug-gestedthatthelimitedmalignancypotentialofsometumorsassociatedwithothertumorsuppressorsyndromessuchasTSCsyndromemaybedue,inpart,totheattenuationofAktsignaling,resultingfromtheexistenceofpotentmTORC1-dependentfeedbackloopswhichstronglysuppresssignalingupstreamofthePI3Kpathway.MultiplemechanismsfornegativefeedbacktoAktsignalinghavebeendescribedpreviously(10,17),oneofwhichappearstoinvolveS6K1-dependentphosphorylationofinsulinreceptorsubstrateproteins,renderingthePI3K-Aktpathwayresistanttoinsu-lin/IGF1stimulationinarapamycin-dependentmanner.Insupportofthispossibility,wefoundthatgrowthfactor(in-sulin)-stimulatedphosphorylationofAktisimpairedincellslackingmerlinandthatprolonged(24-h)rapamycintreat-mentcanrestoreAktphosphorylationundergrowthcondi-tionswithfullserum.However,itremainstobeestablishedwhetherthestateofthismTOR-dependentfeedbackmech-anismiswhatdelineatesthemalignancyofthesetumors.OurﬁndingsidentifymTORC1asacriticalregulatorofmeningiomaandschwannomagrowthinvitroandinvivo,suggestingthatmTORinhibitionmayprovidenewavenuesfortargetedtherapiestoarrestthegrowthofthesetumors.Rapa-mycinandrapamycinanalogshaveshownantitumoractivityacrossavarietyofhumancancersinclinicaltrials,andearlysuccessesinthetreatmentofbenignhamartomasyndromeslikeTSChavebeenreported(2,8).However,theexistenceofastrongnegativefeedbackloopfromS6K1toAktsignalingpresentsapotentialtherapeuticproblem,aslosingthisfeed-backinhibitionmaypromotecellsurvivalandchemoresis-tance.Therefore,dualinhibitionofthePI3KpathwayandmTORmaybeaneffectivestrategy.Interestingly,insomecelltypes,prolongedrapamycintreatmentinhibitedmTORC2as-semblyand,consequently,Aktphosphorylation,suggestingthatclinicalresponsestorapamycinmayresultfromtheinhi-bitionofbothmTORCs(34).Givenourﬁndings,webelievethatrapamycinmeritsconsiderationforclinicalstudiesasatherapeuticagent,eitheraloneorincombinationwithPI3Kpathwayinhibitors,againstNF2-associatedtumors.ACKNOWLEDGMENTSWeareindebtedtoJosephAvruch(MGH)forvaluablediscussions.WethankRobertaL.Beauchampforexperttechnicalassistanceandmembersofourlaboratoryforhelpfulcommentsonthemanuscript.ThisworkwassupportedbytheNationalInstituteofHealthgrantsNS024279andMH079213,theS.SydneyDeYoungFoundation,andNeuroﬁbromatosis,Inc.,NewEngland.PackagingandproductionofviralsupernatantsforlentiviralinfectionsweresupportedbytheNIHCoreFacilitygrantNS045776.REFERENCES1.Averous,J.,B.D.Fonseca,andC.G.Proud.2008.RegulationofcyclinD1expressionbymTORC1signalingrequireseukaryoticinitiationfactor4E-bindingprotein1.Oncogene27:1106–1113.2.Bissler,J.J.,F.X.McCormack,L.R.Young,J.M.Elwing,G.Chuck,J.M.Leonard,V.J.Schmithorst,T.Laor,A.S.Brody,J.Bean,S.Salisbury,andD.N.Franz.2008.Sirolimusforangiomyolipomaintuberoussclerosiscom-plexorlymphangioleiomyomatosis.N.Engl.J.Med.358:140–151.3.Bretscher,A.,K.Edwards,andR.G.Fehon.2002.ERMproteinsandmerlin:integratorsatthecellcortex.Nat.Rev.Mol.CellBiol.3:586–599.4.Brunn,G.J.,J.Williams,C.Sabers,G.Wiederrecht,J.C.Lawrence,Jr.,andR.T.Abraham.1996.Directinhibitionofthesignalingfunctionsofthemammaliantargetofrapamycinbythephosphoinositide3-kinaseinhibitors,wortmanninandLY294002.EMBOJ.15:5256–5267.5.Cai,S.L.,A.R.Tee,J.D.Short,J.M.Bergeron,J.Kim,J.Shen,R.Guo,C.L.Johnson,K.Kiguchi,andC.L.Walker.2006.ActivityofTSC2isinhibitedbyAKT-mediatedphosphorylationandmembranepartitioning.J.CellBiol.173:279–289.6.Claus,E.B.,M.L.Bondy,J.M.Schildkraut,J.L.Wiemels,M.Wrensch,andP.M.Black.2005.Epidemiologyofintracranialmeningioma.Neuro-surgery57:1088–1095.7.Counter,C.M.,W.C.Hahn,W.Wei,S.D.Caddle,R.L.Beijersbergen,P.M.Lansdorp,J.M.Sedivy,andR.A.Weinberg.1998.Dissociationamonginvitrotelomeraseactivity,telomeremaintenance,andcellularimmortaliza-tion.Proc.Natl.Acad.Sci.USA95:14723–14728.8.Franz,D.N.,J.Leonard,C.Tudor,G.Chuck,M.Care,G.Sethuraman,A.Dinopoulos,G.Thomas,andK.R.Crone.2006.Rapamycincausesregres-sionofastrocytomasintuberoussclerosiscomplex.Ann.Neurol.59:490–498.9.Goncharova,E.,D.Goncharov,D.Noonan,andV.P.Krymskaya.2004.TSC2modulatesactincytoskeletonandfocaladhesionthroughTSC1-bind-ingdomainandtheRac1GTPase.J.CellBiol.167:1171–1182.10.Guertin,D.A.,andD.M.Sabatini.2007.DeﬁningtheroleofmTORincancer.CancerCell12:9–22.11.Gusella,J.F.,V.Ramesh,M.MacCollin,andL.B.Jacoby.1996.Neuroﬁ-bromatosis2:lossofmerlin’sprotectivespell.Curr.Opin.Genet.Dev.6:87–92.12.Gutmann,D.H.,A.Aylsworth,J.C.Carey,B.Korf,J.Marks,R.E.Pyeritz,A.Rubenstein,andD.Viskochil.1997.Thediagnosticevaluationandmul-tidisciplinarymanagementofneuroﬁbromatosis1andneuroﬁbromatosis2.JAMA278:51–57.13.Haddad,L.A.,N.Smith,M.Bowser,Y.Niida,V.Murthy,C.Gonzalez-Agosti,andV.Ramesh.2002.TheTSC1tumorsuppressorhamartininteractswithneuroﬁlament-Landpossiblyfunctionsasanovelintegratoroftheneuronalcytoskeleton.J.Biol.Chem.277:44180–44186.14.Hamaratoglu,F.,M.Willecke,M.Kango-Singh,R.Nolo,E.Hyun,C.Tao,H.Jafar-Nejad,andG.Halder.2006.Thetumour-suppressorgenesNF2/MerlinandExpandedactthroughHipposignallingtoregulatecellprolif-erationandapoptosis.Nat.CellBiol.8:27–36.15.Han,S.,T.M.Santos,A.Puga,J.Roy,E.A.Thiele,M.McCollin,A.Stemmer-Rachamimov,andV.Ramesh.2004.Phosphorylationoftuberinasanovelmechanismforsomaticinactivationofthetuberoussclerosiscomplexproteinsinbrainlesions.CancerRes.64:812–816.16.Huang,J.,C.C.Dibble,M.Matsuzaki,andB.D.Manning.2008.TheTSC1-TSC2complexisrequiredforproperactivationofmTORcomplex2.Mol.Cell.Biol.28:4104–4115.17.Huang,J.,andB.D.Manning.2008.TheTSC1-TSC2complex:amolecularswitchboardcontrollingcellgrowth.Biochem.J.412:179–190.18.Jacinto,E.,R.Loewith,A.Schmidt,S.Lin,M.A.Ruegg,A.Hall,andM.N.Hall.2004.MammalianTORcomplex2controlstheactincytoskeletonandisrapamycininsensitive.Nat.CellBiol.6:1122–1128.19.James,M.F.,J.M.Lelke,M.Maccollin,S.R.Plotkin,A.O.Stemmer-Rachamimov,V.Ramesh,andJ.F.Gusella.2008.ModelingNF2withhumanarachnoidalandmeningiomacellculturesystems:NF2silencingreﬂectsthebenigncharacteroftumorgrowth.Neurobiol.Dis.29:278–292.20.Johnson,M.D.,A.Woodard,P.Kim,andM.Frexes-Steed.2001.Evidenceformitogen-associatedproteinkinaseactivationandtransductionofmito-genicsignalsbyplatelet-derivedgrowthfactorinhumanmeningiomacells.J.Neurosurg.94:293–300.21.Kleihues,P.,D.N.Louis,B.W.Scheithauer,L.B.Rorke,G.Reifenberger,P.C.Burger,andW.K.Cavenee.2002.TheW.H.O.classiﬁcationoftumorsofthenervoussystem.J.Neuropathol.Exp.Neurol.61:215–229.22.Kwiatkowski,D.J.2003.Tuberoussclerosis:fromtuberstomTOR.Ann.Hum.Genet.67:87–96.23.Lallemand,D.,M.Curto,I.Saotome,M.Giovannini,andA.I.McClatchey.2003.NF2deﬁciencypromotestumorigenesisandmetastasisbydestabilizingadherensjunctions.GenesDev.17:1090–1100.24.Lamb,R.F.,C.Roy,T.J.Diefenbach,H.V.Vinters,M.W.Johnson,D.G.Jay,andA.Hall.2000.TheTSC1tumoursuppressorhamartinregulatescelladhesionthroughERMproteinsandtheGTPaseRho.Nat.CellBiol.2:281–287.25.Ma,L.,Z.Chen,H.Erdjument-Bromage,P.Tempst,andP.P.Pandolﬁ.2005.PhosphorylationandfunctionalinactivationofTSC2byErk:implica-tionsfortuberoussclerosisandcancerpathogenesis.Cell121:179–193.26.Manning,B.D.2004.BalancingAktwithS6K:implicationsforbothmeta-bolicdiseasesandtumorigenesis.J.CellBiol.167:399–403.27.McClatchey,A.I.,andM.Giovannini.2005.Membraneorganizationand4260JAMESETAL.MOL.CELL.BIOL.tumorigenesis—theNF2tumorsuppressor,Merlin.GenesDev.19:2265–2277.28.Morrison,H.,L.S.Sherman,J.Legg,F.Banine,C.Isacke,C.A.Haipek,D.H.Gutmann,H.Ponta,andP.Herrlich.2001.TheNF2tumorsuppressorgeneproduct,merlin,mediatescontactinhibitionofgrowththroughinter-actionswithCD44.GenesDev.15:968–980.29.Okada,T.,M.Lopez-Lago,andF.G.Giancotti.2005.Merlin/NF-2mediatescontactinhibitionofgrowthbysuppressingrecruitmentofRactotheplasmamembrane.J.CellBiol.171:361–371.30.Perry,A.,D.H.Gutmann,andG.Reifenberger.2004.Molecularpathogen-esisofmeningiomas.J.Neurooncol.70:183–202.31.Rouleau,G.A.,P.Merel,M.Lutchman,M.Sanson,J.Zucman,C.Mari-neau,K.Hoang-Xuan,S.Demczuk,C.Desmaze,B.Plougastel,S.M.Pulst,G.Lenoir,E.Bijlsma,L.Fashold,J.Dumanski,P.deJong,D.Parry,R.Eldrige,A.Aurias,O.Delattre,andG.Thomas.1993.Alterationinanewgeneencodingaputativemembrane-organizingproteincausesneuro-ﬁbro-matosistype2.Nature363:515–521.32.Roux,P.P.,B.A.Ballif,R.Anjum,S.P.Gygi,andJ.Blenis.2004.Tumor-promotingphorbolestersandactivatedRasinactivatethetuberoussclerosistumorsuppressorcomplexviap90ribosomalS6kinase.Proc.Natl.Acad.Sci.USA101:13489–13494.33.Ruttledge,M.H.,J.Sarrazin,S.Rangaratnam,etal.1994.EvidenceforthecompleteinactivationoftheNF2geneinthemajorityofsporadicmeningi-omas.Nat.Genet.6:180–184.34.Sabatini,D.M.2006.mTORandcancer:insightsintoacomplexrelation-ship.Nat.Rev.Cancer6:729–734.35.Sancak,Y.,C.C.Thoreen,T.R.Peterson,R.A.Lindquist,S.A.Kang,E.Spooner,S.A.Carr,andD.M.Sabatini.2007.PRAS40isaninsulin-regulatedinhibitorofthemTORC1proteinkinase.Mol.Cell25:903–915.36.Sarbassov,D.D.,S.M.Ali,S.Sengupta,J.H.Sheen,P.P.Hsu,A.F.Bagley,A.L.Markhard,andD.M.Sabatini.2006.ProlongedrapamycintreatmentinhibitsmTORC2assemblyandAkt/PKB.Mol.Cell22:159–168.37.Sena-Esteves,M.,J.C.Tebbets,S.Steffens,T.Crombleholme,andA.W.Flake.2004.Optimizedlarge-scaleproductionofhightiterlentivirusvectorpseudotypes.J.Virol.Methods122:131–139.38.Shamah,S.M.,J.A.Alberta,W.V.Giannobile,A.Guha,Y.K.Kwon,R.S.Carroll,P.M.Black,andC.D.Stiles.1997.Detectionofactivatedplatelet-derivedgrowthfactorreceptorsinhumanmeningioma.CancerRes.57:4141–4147.39.Sherman,L.,H.M.Xu,R.T.Geist,S.Saporito-Irwin,N.Howells,H.Ponta,P.Herrlich,andD.H.Gutmann.1997.InterdomainbindingmediatestumorgrowthsuppressionbytheNF2geneproduct.Oncogene15:2505–2509.40.Surace,E.I.,C.A.Haipek,andD.H.Gutmann.2004.Effectofmerlinphosphorylationonneuroﬁbromatosis2(NF2)genefunction.Oncogene23:580–587.41.Trofatter,J.A.,M.M.MacCollin,J.L.Rutter,J.R.Murrell,M.P.Duyao,D.M.Parry,R.Eldridge,N.Kley,A.G.Menon,K.Pulaski,V.H.Haase,C.M.Ambrose,D.Munroe,C.Bove,J.L.Haines,R.L.Martuza,M.E.MacDonald,B.R.Seizinger,M.P.Short,A.J.Buckler,andJ.F.Gusella.1993.Anovelmoesin-,ezrin-,radixin-likegeneisacandidatefortheneu-roﬁbromatosis2tumorsuppressor.Cell72:791–800.42.VanderHaar,E.,S.I.Lee,S.Bandhakavi,T.J.Grifﬁn,andD.H.Kim.2007.InsulinsignallingtomTORmediatedbytheAkt/PKBsubstratePRAS40.Nat.CellBiol.9:316–323.43.Vanhaesebroeck,B.,S.J.Leevers,K.Ahmadi,J.Timms,R.Katso,P.C.Driscoll,R.Woscholski,P.J.Parker,andM.D.Waterﬁeld.2001.Synthesisandfunctionof3-phosphorylatedinositollipids.Annu.Rev.Biochem.70:535–602.44.Wiederhold,T.,M.F.Lee,M.James,R.Neujahr,N.Smith,A.Murthy,J.Hartwig,J.F.Gusella,andV.Ramesh.2004.Magicin,anovelcytoskeletalproteinassociateswiththeNF2tumorsuppressormerlinandGrb2.Onco-gene23:8815–8825.45.Wullschleger,S.,R.Loewith,andM.N.Hall.2006.TORsignalingingrowthandmetabolism.Cell124:471–484.46.Yang,Q.,andK.L.Guan.2007.ExpandingmTORsignaling.CellRes.17:666–681.47.Zhang,H.,G.Cicchetti,H.Onda,H.B.Koon,K.Asrican,N.Bajraszewski,F.Vazquez,C.L.Carpenter,andD.J.Kwiatkowski.2003.LossofTsc1/Tsc2activatesmTORanddisruptsPI3K-AktsignalingthroughdownregulationofPDGFR.J.Clin.Investig.112:1223–1233.48.Zhang,H.H.,A.I.Lipovsky,C.C.Dibble,M.Sahin,andB.D.Manning.2006.S6K1regulatesGSK3underconditionsofmTOR-dependentfeedbackinhibitionofAkt.Mol.Cell24:185–197.49.Zhao,B.,X.Wei,W.Li,R.S.Udan,Q.Yang,J.Kim,J.Xie,T.Ikenoue,J.Yu,L.Li,P.Zheng,K.Ye,A.Chinnaiyan,G.Halder,Z.C.Lai,andK.L.Guan.2007.InactivationofYAPoncoproteinbytheHippopathwayisinvolvedincellcontactinhibitionandtissuegrowthcontrol.GenesDev.21:2747–2761.VOL.29,2009NF2/MERLINREGULATESmTORC1SIGNALING4261